Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 112Recurrence 34Neoplasms, Plasma Cell 10Neoplasms 9Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 3Renal Insufficiency 2Primary Myelofibrosis 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Sarcoma 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

dacetuzumab 7blinatumomab 6Rituximab 5ibrutinib 3Cyclophosphamide 3venetoclax 2tetulomab tetraxetan lu-177 2ponatinib 2fludarabine 2ferric carboxymaltose 2cobomarsen 2Vorinostat 2Valganciclovir 2Lutetium 2Lenalidomide 2Ifosfamide 2Ganciclovir 2Everolimus 2Dexamethasone 2Bortezomib 2ruxolitinib 1pomalidomide 1pegaspargase 1ficlatuzumab 1epratuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoproliferative Disorders × pomalidomide × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡